TEPMETKO 225 MG TAB (TEPOTINIB)

Tepmetko (Tepotinib) is an oral medication approved for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

🧬 Composition & Classification

• Generic Name: Tepotinib

• Brand Name: Tepmetko

• Drug Class: MET Tyrosine Kinase Inhibitor

• Manufacturer: EMD Serono 

             Tepotinib selectively inhibits the MET receptor tyrosine kinase, which is involved in tumor cell proliferation, survival, and metastasis.

📋 Indications

     Tepmetko is indicated for the treatment of adult patients with metastatic NSCLC whose tumors have a mutation leading to MET exon 14 skipping, as detected by an FDA-approved test.

💊 Dosage & Administration

• Recommended Dosage: 450 mg orally once daily with food.

• Administration Instructions:

  • Take at approximately the same time each day.

  • Swallow tablets whole; do not chew, crush, or split.

  • If a dose is missed and it’s more than 8 hours until the next dose, take it as soon as possible. If less than 8 hours remain, skip the missed dose.

  • If vomiting occurs after taking a dose, do not take an additional dose; take the next dose at the scheduled time.

⚠️ Warnings & Precautions

• Interstitial Lung Disease (ILD)/Pneumonitis: Tepmetko may cause severe or life-threatening ILD/pneumonitis. Monitor for new or worsening respiratory symptoms. Permanently discontinue if ILD is confirmed.

• Hepatotoxicity: Elevations in liver enzymes (ALT, AST) can occur. Monitor liver function tests before and during treatment. Adjust dose or discontinue if severe liver injury is suspected.

• Embryo-Fetal Toxicity: Tepmetko can cause fetal harm. Advise females of reproductive potential to use effective contraception during treatment and for one week after the last dose.

⚠️ Side Effects

       Common Side Effects :

• Edema (swelling)

• Nausea

• Fatigue

• Diarrhea

• Musculoskeletal pain

• Dyspnea (shortness of breath)

• Decreased appetite

• Rash

        Serious Adverse Reactions :

• Pleural effusion

• Pneumonia

• Edema

• General health deterioration

• Dyspnea

• Musculoskeletal pain

• Pulmonary embolism

✅ Conclusion

Tepmetko (Tepotinib) offers a targeted treatment option for patients with metastatic NSCLC harboring MET exon 14 skipping alterations. Its once-daily oral dosing provides convenience; however, patients should be closely monitored for potential serious side effects, including interstitial lung disease and liver toxicity. Healthcare providers should ensure appropriate patient selection and counseling regarding the risks and benefits of therapy